cf/Aware

All about Cystic Fibrosis. Always refer to your team for specialist advice. Oh and we don't always agree with RTs.

[cf/Aware @CFAware]

Kalydeco = ivacaftor
Orkambi = lumacaftor + ivacaftor
Symkevi = tezacaftor + ivacaftor
Kaftrio = elexacaftor+tezacaftor+ ivacaftor

[Alan Smyth @AlanRSmyth]

Excited to offer participation in GRAMPUS-CF to patients with cystic fibrosis worldwide. Just click on the link to join the study! https://t.co/EnAha4Gjfo @cftrust @CF_Foundation @alloonsl @CFAware

[Adam Feuerstein ✡️ @adamfeuerstein]

$VRTX on pace to lose $15B in market value today.

[Vertex Pharmaceuticals @VertexPharma]

Today the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for our fifth cystic fibrosis (CF) medicine. This is an important step towards our goal of treating all people living with CF.

[cf/Aware @CFAware]

https://t.co/XDQ9B3zjZJ

[Vertex Pharmaceuticals @VertexPharma]

Today the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for the label expansion of our fourth cystic fibrosis (CF) medicine to include an expanded population with certain mutations. This marks an important step towards our goal of treating all people with CF.

[cf/Aware @CFAware]

Mycobacterium Abscessus Infections and Cystic Fibrosis | Nature Research Intelligence https://t.co/X50FuthoTE

[cf/Aware @CFAware]

Cystic Fibrosis and Fungal Infections | Nature Research Intelligence https://t.co/DHPwX0o8ou

[cf/Aware @CFAware]

Cystic Fibrosis and Bone Health | Nature Research Intelligence https://t.co/EuBdJxzZ9t

[cf/Aware @CFAware]

Do intravenous antibiotics improve pulmonary exacerbations (flare-ups) in people with cystic fibrosis? | Cochrane https://t.co/gZTLfY5CEx

[cf/Aware @CFAware]

Body composition changes and clinical outcomes in pediatric cystic fibrosis during 24 months of lumacaftor ivacaftor therapy based on real-world data | Scientific Reports https://t.co/byCtlTdKxw

[The Lancet Respiratory Medicine @LancetRespirMed]

🚨 New in The Lancet Respiratory Medicine

Phase 3 data on vanzacaftor–tezacaftor–deutivacaftor in #cysticfibrosis

Read open access here:
Patients aged 6–11 years https://t.co/d7R7w1hsgo
Patients aged 12 years and older https://t.co/Xl4qJtcS2C

[cf/Aware @CFAware]

https://t.co/bjfUxioktF

[cf/Aware @CFAware]

#NewProfilePic

[Dr Katie Gathercole @katieguacamole]

GRAMPUS-CF aims to understand gut symptoms in people with cystic fibrosis (CF)
so that we can develop treatments. If you are a person with CF, you can help! Visit
our website for participant information, online consent and to download the app.
https://t.co/FoOUpNDK8x Thank you!

[cf/Aware @CFAware]

NICE Board says new method allowing greater weight to be given to severe diseases is working | NICE https://t.co/z4ipgrGuhS

[cf/Aware @CFAware]

Boy, 3, has combination of CFTR mutations, no CF symptoms: Report https://t.co/UKuY4HpBoC

[cf/Aware @CFAware]

NICE approves three cystic fibrosis drugs for NHS use - The Pharmaceutical Journal https://t.co/0tgbcJ4o3h

[Robert Sandler @RobertDSandler]

UK #CysticFibrosis community! Tell us about your thoughts on inhaled meds & interacting with your care providers post-Kaftrio in this anonymous 5-10 min research survey. Your voice matters! Please share! [https://t.co/HDX6Qjf1CY] #CF

[Eli Fritz McDonald @EliFritzMcD]

Trikafta revolutionized treatment for Cystic Fibrosis, reaching >90% of patients variants.

But what about the remaining untreatable 10%?

We studied several poorly responsive, FDA-unapproved variants and paved a path forward for drug development.

https://t.co/cGQOqYegwe 1/7

[cf/Aware @CFAware]

CF patients eat high-fat diet despite guidelines: Review https://t.co/e9dk6lhRPS